Results 121 to 130 of about 3,869 (167)
Levosimendan vs. Dobutamine in Patients with Septic Shock: A Systematic Review and Meta-Analysis with Trial Sequential Analysis. [PDF]
J Clin MedRodríguez EE +5 more
europepmc +1 more source
Vasoactive Medications and the Microcirculation in Septic Shock: A Scoping Review. [PDF]
Crit Care MedSathianathan S +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Pediatric Intensive Care, 2015 We designed this review to examine the mechanism of action of levosimendan (Simdax®, Orion Pharma, Espoo, Finland) and its current clinical application in critically ill adults and children with acutely decompensated severe congestive heart failure and who require inotropic support.
Asher, Levin, Gideon, Paret
openaire +3 more sources
Drugs, 2001
Levosimendan, a pyridazinone-dinitrile derivative, is a calcium sensitiser with additional action on adenosine triphosphate (ATP)-sensitive potassium channels. It is used intravenously (IV) for the treatment of decompensated cardiac failure. At therapeutic doses, levosimendan exhibits enhanced contractility with no increase in oxygen demands.
D P, Figgitt, P S, Gillies, K L, Goa
+5 more sources
Levosimendan, a pyridazinone-dinitrile derivative, is a calcium sensitiser with additional action on adenosine triphosphate (ATP)-sensitive potassium channels. It is used intravenously (IV) for the treatment of decompensated cardiac failure. At therapeutic doses, levosimendan exhibits enhanced contractility with no increase in oxygen demands.
D P, Figgitt, P S, Gillies, K L, Goa
+5 more sources
Current Pharmaceutical Design, 2013
During the last years an increasing number of patients with high perioperative risk and decreased left ventricular function are referred to cardiac and non-cardiac surgery. In this subgroup of patients, heart failure is the major cause of perioperative morbidity and mortality. In order to prevent and treat this type of complications several therapeutic
Andrea, Rognoni +7 more
openaire +2 more sources
During the last years an increasing number of patients with high perioperative risk and decreased left ventricular function are referred to cardiac and non-cardiac surgery. In this subgroup of patients, heart failure is the major cause of perioperative morbidity and mortality. In order to prevent and treat this type of complications several therapeutic
Andrea, Rognoni +7 more
openaire +2 more sources
Clinical Pharmacology of Levosimendan
Clinical Pharmacokinetics, 2007Levosimendan has been developed for the treatment of decompensated heart failure and is used intravenously when patients with heart failure require immediate initiation of drug therapy. It increases cardiac contractility and induces vasodilatation.
Saila, Antila +2 more
openaire +2 more sources
Levosimendan: Implications for Clinicians
The Journal of Clinical Pharmacology, 2003Levosimendan is a novel calcium sensitizing agent in development for the treatment of acute and chronic heart failure. The agent increases myocardial force without increasing myocyte calcium concentrations, thus reducing the possibility for myocardial necrosis.
Brian F, McBride, C Michael, White
openaire +2 more sources